Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed yesterday at ...
LONDON (Reuters) - Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, its chief executive said on Wednesday, but it is ...
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
No Plan to Prop up Global Health, Novo Nordisk Foundation Says, as Trump Freezes US Aid By Jennifer Rigby LONDON (Reuters) - The Novo Nordisk Foundation does not plan to step in to prop up a ...
A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a ...
Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...
Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.
While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...